<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<records>
   <record>
      <language>eng</language>
      <journalTitle>Journal of Medical Research and Health Sciences</journalTitle>
      <eissn>2589-9031</eissn>
      <publicationDate/>
      <volume>4</volume>
      <startPage/>
      <doi>https://doi.org/10.15520/jmrhs.v4i3.319</doi>
      <publisherRecordId/>
      <documentType>article</documentType>
      <title language="eng">Melatonin as a potential adjunctive therapy for COVID-19</title>
      <authors/>
      <affiliationsList/>
      <abstract language="eng">The global pandemic of COVID-19 has created historic and devastating impact. The pathophysiology and adverse clinical effects, are attributed to the uncontrolled inflammatory cascades and immune responses attributed to a “cytokine storm”. Melatonin has shown its role in anti-inflammation, antioxidant, and immunomodulation and proposes potential therapeutic tool against COVID-19. The clinical data and safety profile of melatonin in COVID-19 are currently under prospective evaluation, however, its efficacy in diseases with chronic inflammation and other viral infections propose potential current benefits of melatonin for COVID-19 infection and sequelae   </abstract>
      <fullTextUrl format="pdf">.pdf</fullTextUrl>
      <keywords language="eng"/>
   </record>
</records>